Last reviewed · How we verify
Methylene Blue MMX tablets
At a glance
| Generic name | Methylene Blue MMX tablets |
|---|---|
| Sponsor | Cosmo Technologies Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Technical Feasibility Evaluation of Mucosal Staining During Colon Capsule Endoscopy (CCE) Procedure in Colorectal Cancer (CRC) High Risk Population, When Using MB-MMX (NA)
- Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX (PHASE2)
- Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy (PHASE2)
- Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA (PHASE2)
- The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy (PHASE3)
- Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylene Blue MMX tablets CI brief — competitive landscape report
- Methylene Blue MMX tablets updates RSS · CI watch RSS
- Cosmo Technologies Ltd portfolio CI